Skip to main content

Fluidigm Begins Early-Access Program for Automated Single-Cell Sample Prep System


Fluidigm said today that it has initiated an early-access program for its new C1 Single-Cell AutoPrep System for single-cell gene expression studies.

The new platform, the company claims, for the first time enables researchers to isolate cells, extract RNA, then reverse transcribe and pre-amplify mRNA transcripts automatically in order to detect and analyze cellular activity.

Fluidigm demonstrated the new system and announced the early-access program at the International Society for Stem Cell Research meeting held this week in Yokohama, Japan.

Under the early-access program, select customers will be able to receive first commercial shipments of the C1 in the second half of this year, prior to the general commercial launch of the instrument.

Early users will also be eligible to receive free consumables, help develop new platform capabilities, and receive pre-market access to future platform expansions, Fluidigm said.

Fluidigm CEO Gajus Worthington first disclosed the development of the C1 last month during a conference call recapping the company's first-quarter 2012 revenues (PCR Insider, 5/17/2012).

Worthington noted at the time that the C1 was expected to bolster Fluidigm's growing single-cell genomics business by helping users of the company's BioMark and BioMark HD platforms reduce sample preparation costs by as much as 50-fold.

He further noted that Fluidigm expects that the C1 may eventually help reduce the cost of conducting single-cell sequencing studies on next-generation sequencing platforms by between 10- and 100-fold.

To use the platform, researchers load a sample of cells in solution into the C1 microfluidic chip in a single pipetting step, then direct the system to rapidly automatically isolate up to 96 individual cells into individual chambers for preparation, Fluidigm said in a statement today.

Users can then choose an "in-process" quality control checkpoint to verify the number of captured cells and distinguish live cells from dead cells to preserve data integrity, the company said. The workflow then proceeds with a rapid "on-chip" cell lysis with RNA purification, reverse transcription, and pre-amplification without hands-on reagent mixing and sample transfer. The final pre-amplified cDNA product is then harvested to collection wells for transfer to the BioMark HD system for quantitative PCR analysis.

Fluidigm said that it expects stem cell, cancer, and immunology research to be the initial focus applications for the system.

"Ultimately, the C1 System will allow researchers to study cell differentiation, measure individual cell responses to specific stimuli, verify critical disease biomarkers, validate RNAi knockdown, and sequence individual cells," Worthington said in a statement.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.